Mackenzie Financial Corp Has $768,000 Position in Balchem Corporation (NASDAQ:BCPC)

Mackenzie Financial Corp increased its position in shares of Balchem Corporation (NASDAQ:BCPC) by 20.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,625 shares of the basic materials company’s stock after buying an additional 785 shares during the quarter. Mackenzie Financial Corp’s holdings in Balchem were worth $768,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. FMR LLC grew its holdings in shares of Balchem by 16.0% during the fourth quarter. FMR LLC now owns 576,994 shares of the basic materials company’s stock worth $94,047,000 after buying an additional 79,499 shares in the last quarter. Northern Trust Corp grew its stake in Balchem by 9.5% in the fourth quarter. Northern Trust Corp now owns 407,054 shares of the basic materials company’s stock valued at $66,348,000 after purchasing an additional 35,152 shares in the last quarter. Congress Asset Management Co. grew its stake in Balchem by 12.9% in the first quarter. Congress Asset Management Co. now owns 358,500 shares of the basic materials company’s stock valued at $59,511,000 after purchasing an additional 40,890 shares in the last quarter. Invesco Ltd. grew its stake in Balchem by 21.2% in the fourth quarter. Invesco Ltd. now owns 228,933 shares of the basic materials company’s stock valued at $37,315,000 after purchasing an additional 40,099 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Balchem by 20,231.2% in the first quarter. GAMMA Investing LLC now owns 177,288 shares of the basic materials company’s stock valued at $29,430,000 after purchasing an additional 176,416 shares in the last quarter. 87.91% of the stock is currently owned by institutional investors.

Balchem Stock Performance

Shares of NASDAQ BCPC opened at $160.00 on Thursday. The company has a current ratio of 2.64, a quick ratio of 1.57 and a debt-to-equity ratio of 0.17. Balchem Corporation has a 12 month low of $145.70 and a 12 month high of $185.96. The stock has a 50 day moving average of $159.43 and a 200-day moving average of $162.16. The company has a market capitalization of $5.19 billion, a P/E ratio of 36.70, a P/E/G ratio of 3.34 and a beta of 0.88.

Balchem (NASDAQ:BCPC) last issued its earnings results on Thursday, July 31st. The basic materials company reported $1.27 EPS for the quarter, topping the consensus estimate of $1.25 by $0.02. Balchem had a return on equity of 12.41% and a net margin of 14.48%. The company had revenue of $255.47 million during the quarter, compared to the consensus estimate of $250.31 million. During the same period in the previous year, the company posted $1.09 EPS. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. As a group, equities research analysts predict that Balchem Corporation will post 4.64 EPS for the current year.

Wall Street Analysts Forecast Growth

BCPC has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $189.00 price target (up from $180.00) on shares of Balchem in a research note on Monday. Wall Street Zen downgraded Balchem from a “buy” rating to a “hold” rating in a research note on Saturday, July 26th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.